Acumen Pharmaceuticals, Inc. (ABOS) — IPO Analysis
By Kian O Connor | Updated 4/29/2026
Company Overview
Performance Overview
Since going public at $16.00 per share on Jul 1, 2021, Acumen Pharmaceuticals, Inc. shares have declined 84.6%, disappointing investors who participated in the IPO. The stock currently trades at $2.46, giving the company a market capitalization of $177.7M.
Lockup Expiration
The lockup period for Acumen Pharmaceuticals, Inc. expired 1583 days ago on Dec 28, 2021. Insiders and early investors are now free to sell their pre-IPO shares. The post-lockup trading period is often volatile as the market absorbs any additional supply from insider selling.
Industry Context
Acumen Pharmaceuticals, Inc. operates in the Biotechnology sector, which has seen varied IPO activity in recent years. The company is headquartered in the United States and is classified under SIC code . Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing ABOS as an investment.
Trading History
Acumen Pharmaceuticals, Inc. is actively trading in the public markets with a current share price of $2.46. The company went public at $16.00 per share, representing a decline of 84.6% from the initial offering price. With a current market capitalization of $177.7M, Acumen Pharmaceuticals, Inc. continues to establish its presence as a publicly traded entity in the Biotechnology.
Important Disclaimer
This analysis of Acumen Pharmaceuticals, Inc. (ABOS) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.